CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.

A reescalating battle between pharmaceutical companies and pharmacy benefit managers is brewing in Washington, D.C., as ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

A CVS spokesperson said the Emory collaboration is the first time MinuteClinic has expanded into primary care services in ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Earnings have fallen but are still strong enough to meet CVS Health's dividend commitment. Management expects adjusted ...

Our drive to greater drug pricing transparency through innovation has never been more needed,” Ed DeVaney says.

Principal Securities Inc. grew its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 3.2% during the fourth ...

Retail pharmacy chain CVS Health (CVS) is scheduled to announce its results for the fourth quarter of 2024 before the market ...

Ed DeVaney’s promotion is the latest leadership shakeup at CVS Health as the company works on a multi-year turnaround plan.

CVS Health (CVS) stock soared about 15% yesterday after posting upbeat fourth-quarter results, with revenues and earnings ...